Related Experiment Video
Updated: Sep 20, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Cardiomyocyte-localized CCDC25 senses NET DNA to promote doxorubicin cardiotoxicity by activating autophagic flux
Man Nie1, Dexin Lei2, Zhou Liu3,4
1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. nieman@sysucc.org.cn.
Abstract:
Cardiotoxicity restricts the clinical use of anthracyclines. Although recent evidence indicates that aberrant activation of the cytosolic DNA-sensing pathway mediates cardiotoxicity, the function of extracellular DNA remains unclear. Here we observe a substantial increase in circulating neutrophil extracellular trap (NET) DNA in individuals with lymphoma experiencing cardiotoxicity after anthracycline-containing treatment. Using mouse models and human organotypic myocardial slices, we demonstrate that doxorubicin induces HMGB1-dependent cardiac NET formation, thereby promoting cardiac remodeling and dysfunction. Mechanistically, extracellular NET DNA is recognized by the transmembrane protein CCDC25 on cardiomyocytes, and their cross-talk generates reactive oxygen species and activates autophagic flux, subsequently impairing cardiac function. Targeting CCDC25 significantly alleviates anthracycline cardiotoxicity and synergizes with the antitumor efficacy of doxorubicin in lymphoma and breast cancer models. Overall, our findings demonstrate a previously unrecognized role of NETs and CCDC25 in anthracycline cardiotoxicity and suggest that targeting CCDC25 could provide a dual therapeutic and cardioprotective advantage.
Insights
Anthracycline chemotherapy causes heart damage. This study reveals neutrophil extracellular traps (NETs) and CCDC25 protein mediate this cardiotoxicity, offering a potential dual-action therapeutic target.
Area of Science:
- Cardiology
- Oncology
- Immunology
Background:
- Cardiotoxicity limits anthracycline use in cancer treatment.
- The role of extracellular DNA in cardiotoxicity is not well understood.
Purpose of the Study:
- To investigate the role of neutrophil extracellular traps (NETs) and extracellular DNA in anthracycline-induced cardiotoxicity.
- To explore CCDC25 as a potential therapeutic target for mitigating cardiotoxicity.
Main Methods:
- Analysis of circulating NET DNA in lymphoma patients undergoing anthracycline treatment.
- Mouse models and human myocardial slices to study doxorubicin-induced cardiac NET formation.
- Investigated the interaction between NET DNA and cardiomyocyte CCDC25.
Main Results:
- Elevated circulating NET DNA observed in patients with cardiotoxicity.
- Doxorubicin induces HMGB1-dependent cardiac NET formation, leading to cardiac remodeling and dysfunction.
- CCDC25 on cardiomyocytes recognizes NET DNA, generating reactive oxygen species and activating autophagic flux, impairing cardiac function.
Conclusions:
- NETs and CCDC25 play a significant role in anthracycline cardiotoxicity.
- Targeting CCDC25 alleviates cardiotoxicity and enhances doxorubicin's antitumor effects in preclinical models.
- CCDC25 inhibition offers a potential dual therapeutic and cardioprotective strategy.
Related Concept Videos
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
The Intrinsic Apoptotic Pathway
DNA Damage can Stall the Cell Cycle
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Anaphase Promoting Complex
Abnormal Proliferation

